{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216735","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2026-05-11T20:05:17+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:53:04.972581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978","bullets":["Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.","Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).","Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.","Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.","Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216735","json":"https://secwatch.observer/filing/0001193125-26-216735.json","markdown":"https://secwatch.observer/filing/0001193125-26-216735.md","text":"https://secwatch.observer/filing/0001193125-26-216735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/0001193125-26-216735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:53:04.972581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e57c83c4a0797cccce942e949948ec68652eca97","claim":"ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2026 results: revenue $17.2 million, net income Net loss ... $13.1 million, EPS loss of $0.45 per diluted common share.","evidence_excerpt":"multiple value-driving milestones over the coming year.” Fiscal Second Quarter Ended March 31, 2026 Financial Results Total revenue for the three months ended March 31, 2026 was $17.2 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), AbbVie’s treatment for hepatitis C virus, compared to $14.9 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/0001193125-26-216735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2026"},{"label":"Revenue","value":"$17.2 million"},{"label":"Net income","value":"Net loss ... $13.1 million"},{"label":"EPS","value":"loss of $0.45 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}